Jennifer Burkey

Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study

Sotirios Tsimikas, Nicholas J. Viney, Steven G. Hughes et al. · The Lancet · 2015 · 460 citations

Lipid Disorder, Pharmacology, Therapeutic Efficacy +7

Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans

Mark J. Graham, Richard Lee, Thomas A. Bell et al. · Circulation Research · 2013 · 364 citations · Full text

Cytotoxicity and genotoxicity of methyleugenol and related congeners — a mechanism of activation for methyleugenol

Jennifer Burkey, John‐Michael Sauer, Charlene A. McQueen et al. · Mutation research. Fundamental and molecular mechanisms of mutagenesis · 2000 · 111 citations

Biochemistry, Related Congeners, Medicine +5

Pharmacological and Pharmacokinetic Properties of a Structurally Novel, Potent, and Selective Metabotropic Glutamate 2/3 Receptor Agonist: In Vitro Characterization of Agonist (–)-(1 R,4 S,5 S,6 S)-4-Amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic Acid (LY404039)

Linda M. Rorick‐Kehn, Bryan G. Johnson, Jennifer Burkey et al. · Journal of Pharmacology and Experimental Therapeutics · 2007 · 93 citations

Disposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in Mice

Rosie Z. Yu, Mark Graham, Noah Post et al. · Molecular Therapy — Nucleic Acids · 2016 · 89 citations · Full text